A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a neuropsychiatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results